

**23 September 2025 (Melbourne, Australia)**  
**Optiscan Imaging Ltd (ASX: OIL)**

## **Issue of New Shares under the Rights Issue**

**Optiscan issues new shares under its fully underwritten pro-rata renounceable entitlement offer raising \$17.75m to fund the next stage of its strategic transformation to a medical device manufacturer and digital healthcare solution provider.**

**Optiscan Imaging Limited (ASX: OIL)** ('Optiscan' or the 'Company') is pleased to announce that it has today issued 208,835,829 fully paid ordinary shares raising \$17,751,045.47 under its fully underwritten pro-rata renounceable entitlement offer that closed on Tuesday, 16<sup>th</sup> September 2025.

Shares were issued as follows:

	Funds raised	Shares
Entitlements applied for through the Offer	\$9,809,000.85	115,400,004
Shares applied for by eligible shareholders through the shortfall	\$155,768.61	1,832,572
Remaining shortfall to be allocated to underwriter	\$7,786,276.51	91,603,253
<b>Total</b>	<b>\$17,751,045.47<sup>1</sup></b>	<b>208,835,829<sup>1</sup></b>

– ends –

This announcement has been authorised for release by the Board of Optiscan.

**For further information, please contact:**

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: [ceo@optiscan.com](mailto:ceo@optiscan.com)

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

<sup>1</sup> Note the total includes ineligible shareholder entitlements in addition to those announced on 19 September 2025.

## About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit [www.optiscan.com](http://www.optiscan.com) or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

## Disclaimer

*All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.*